JACN Did you know that you can get alerts when a new issue is online?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hatakka, K.
Right arrow Articles by Korpela, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hatakka, K.
Right arrow Articles by Korpela, R.
Journal of the American College of Nutrition, Vol. 27, No. 4, 441-447 (2008)
Published by the American College of Nutrition

Lactobacillus rhamnosus LC705 Together with Propionibacterium freudenreichii ssp shermanii JS Administered in Capsules Is Ineffective in Lowering Serum Lipids

Katja Hatakka, PhD, Marja Mutanen, PhD, Reetta Holma, PhD, Maija Saxelin, PhD and Riitta Korpela, PhD

Department of Applied Chemistry and Microbiology, Nutrition, (K.H., M.M.)
Institute of Biomedicine, Pharmacology, University of Helsinki, Finland (R.H., R.K.)
Valio Ltd, R&D, (K.H., M.S., R.K.)
Foundation for Nutrition Research (R.K.), Helsinki, FINLAND

Address reprint requests to: Prof. Riitta Korpela, Foundation for Nutrition Research, P.O. Box 30, FIN-00039 Helsinki, FINLAND. E-mail: riitta.korpela{at}valio.fi

Objective: The aim of this study was to examine the effect of the administration of Lactobacillus rhamnosus strain LC705 and Propionibacterium freudenreichii ssp shermanii strain JS in capsules on serum cholesterol and triglyceride levels in mildly or moderately hypercholesterolemic men.

Methods: Thirty-eight basically healthy men, mean age 42 years (range 24–55), mean cholesterol 6.2 mmol/L (5.3–8.2 mmol/L), participated in this double-blind, randomised, placebo-controlled, two-period crossover study with 4-week treatment periods. The subjects consumed daily two probiotic capsules containing viable Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii ssp shermanii JS (2 x 1010 colony forming units of each strain daily) or two placebo capsules. Serum lipids were assessed before the intervention, at the end of both 4-week treatment periods, and 2 weeks after the second treatment period. Dietary and lifestyle habits were carefully monitored.

Results: All the subjects completed the study, and the probiotic capsules were well tolerated. Dietary habits and the intake of energy and nutrients, such as saturated fatty acids and cholesterol, did not differ between the treatment groups. No changes in total cholesterol, HDL cholesterol, LDL cholesterol or triglyceride levels were observed during the consumption of the probiotics compared to placebo.

Conclusions: The administration of Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii ssp shermanii JS did not affect serum lipids.

Key words: serum lipids, Lactobacillus rhamnosus LC705, Propionibacterium freudenreichii ssp shermanii JS, capsule, crossover study






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American College of Nutrition.